NDA 209229 · Biocorrx Pharms
Lucemyra
Lofexidine Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 16, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
40
6 Phase 3, 1 recruiting
FAERS reports
163
46 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 22, 2026.
Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. Lofexidine tablets are a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. ( 1 )
Mechanism: Lofexidine tablets are a central alpha-2 adrenergic agonist that binds to receptors on adrenergic neurons. This reduces the release of norepinephrine and decreases sympathetic tone.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 16, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- LUCEMYRA · LOFEXIDINE HYDROCHLORIDE EQ 0.18MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lofexidine" as an intervention, any sponsor and status, largest first.
- Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid WithdrawalPivotal-lookingCompleted
USWM, LLC (dba US WorldMeds)Industry
NCT01863186 · 603 participants · Start Jun 2013 · Primary completion Nov 2014
Drug: Lofexidine HCl; Placebo and 1 more · For: Opioid Dependence; Acute Opioid Withdrawal Syndrome
Sites: Clovis, California; Escondido, California; San Diego, California · 18 sites in all
- Open-Label, Safety Study of LofexidinePivotal-lookingCompleted
USWM, LLC (dba US WorldMeds)Industry
NCT02363998 · 286 participants · Start Feb 2015 · Primary completion Sep 2015
Drug: Lofexidine · For: Opioid Withdrawal
Sites: Little Rock, Arkansas; Springdale, Arkansas; San Diego, California · 18 sites in all
- Lofexidine for Inpatient Opiate DetoxPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00235729 · 264 participants · Start Jun 2006 · Primary completion Oct 2007
Drug: Lofexidine; Placebo · For: Opiate Addiction
Sites: Cerritos, California; Washington D.C., District of Columbia; Atlanta, Georgia · 16 sites in all
- Sublingual Dexmedetomidine for Treating Opioid WithdrawalPivotal-lookingActive, not recruiting
New York State Psychiatric InstituteAcademic, hospital or other
NCT05712707 · 160 participants (planned) · Start Feb 28, 2023 · Primary completion Jun 30, 2025
Drug: BXCL501 (180 micrograms); BXCL501 (240 micrograms) · For: Opioid Use Disorder; Opioid Withdrawal
Sites: New Haven, Connecticut; Eatontown, New Jersey; Marlton, New Jersey · 4 sites in all
- Combined Pharmacotherapy for Cannabis DependencyPivotal-lookingCompleted
New York State Psychiatric InstituteAcademic, hospital or other
NCT01020019 · 156 participants · Start Jan 2010 · Primary completion Sep 2014
Drug: Dronabinol; Placebo and 1 more · For: Cannabis Dependence; Marijuana Dependence
Sites: New York, New York
- Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid WithdrawalPivotal-lookingTerminated
University of PennsylvaniaAcademic, hospital or other
NCT05995535 · 112 participants · Start Sep 1, 2024 · Primary completion Aug 31, 2026
Drug: LFX/PGB; LFX/PLA-PGB · For: Opiate Withdrawal Syndrome; Opioid Use
Sites: Baltimore, Maryland; Philadelphia, Pennsylvania
- Impact of Lofexidine on Stress, Craving and Opioid UsePivotal-lookingCompleted
Medical University of South CarolinaAcademic, hospital or other
NCT03718065 · 112 participants · Start Jun 26, 2019 · Primary completion Jan 30, 2024
Drug: Lofexidine; Placebo · For: Opioid-use Disorder; Opiate Dependence
Sites: Charleston, South Carolina
- Lofexidine for Inpatient Opiate Detox in SingaporePivotal-lookingCompleted
Institute of Mental Health, SingaporeAcademic, hospital or other
NCT01675648 · 112 participants · Start Aug 2012 · Primary completion Jul 2015
Drug: Lofexidine; Diazepam and 2 more · For: Opiate Dependent Patients Who Are Undergoing Inpatient Detoxification in Singapore
Sites: Singapore, Singapore
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness24
- hypotension17
- somnolence15
- dyspnoea14
- diarrhoea13
- dry mouth11
- fatigue11
- insomnia11
- malaise10
- vomiting10
- withdrawal syndrome10
- drug withdrawal syndrome9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 6 |
| 2018 | 19 |
| 2019 | 68 |
| 2020 | 23 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 5 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lucemyra (Lofexidine HCl)
2024 spending
$1.9M
Beneficiaries
446
597 claims
Per beneficiary
$4,359
$23.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,214,485 |
| 2022 | $2,479,909 |
| 2023 | $3,148,076 |
| 2024 | $1,944,300 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Opioid dependence.
O'Shea J, Law F, Melichar J · BMJ Clin Evid 2007 · Systematic Review
- Opioid dependence.
O'Shea J, Law F, Melichar J · BMJ Clin Evid 2009 · Systematic Review
- Opioid dependence.
Praveen KT, Law F, O'Shea J, et al. · BMJ Clin Evid 2011 · Systematic Review
- Buprenorphine for managing opioid withdrawal.
Gowing L, Ali R, White JM, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Alpha-2 Agonists in Autism Spectrum Disorder: A Systematic Review.
Kaye AD, Green AM, Claude JT, et al. · Adv Ther 2024 · Systematic Review
- Effect of lofexidine on cardiac repolarization during treatment of opioid withdrawal.
Darpö B, Pirner M, Longstreth J, et al. · Drug Alcohol Depend 2019 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Biocorrx Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.